Journal article icon

Journal article

Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors.

Abstract:

PURPOSE: Copper chelation reduces the secretion of many angiogenic factors and reduces tumor growth and microvascular density in animal models. ATN-224 is a second-generation analogue of ammonium tetrathiomolybdate. The aim of our phase I study was to reduce serum copper levels, as measured by ceruloplasmin, to 5 to 15 mg/dL (normal 16-60) in 14 to 21 days, to determine the pharmacokinetic profile of ATN-224 and to evaluate dose-limiting toxicities. PATIENTS AND METHODS: Cohorts of patients ...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


Expand authors...
Journal:
Clinical cancer research : an official journal of the American Association for Cancer Research
Volume:
14
Issue:
22
Pages:
7526-7534
Publication date:
2008-11-05
DOI:
EISSN:
1557-3265
ISSN:
1078-0432
URN:
uuid:3f10ca62-8078-4051-970a-b298796c9cb2
Source identifiers:
119300
Local pid:
pubs:119300

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP